research 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
TAK-279 effectively reduces psoriasis symptoms and is safe.
Search
for
Sort by
Research
60-90 / 1000+ results
research Eosinophilia associated with clozapine – A case report
A patient's allergic reaction to clozapine resolved without stopping the medication, showing the importance of blood monitoring.
research Adverse Cutaneous Reactions to Antipsychotics
Some patients taking antipsychotic medications experience skin reactions, ranging from mild to severe.
research Dipyridamole-Associated Shock and Pulmonary Edema; Oxcarbazepine-Induced Resistant Ventricular Fibrillation; Finasteride-Induced Pseudoporphyria; Suicidal Ideation Associated with Asenapine; Rediscovering Adverse Anticholinergic Effects; Prevalence of Adverse Drug Events in Ambulatory Care
research The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
The effect of GLP-1 RAs on erectile function is unclear and needs more research.
research NEW PROPRIETARY BRANDS: Cefaclor monohydrate
Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
research Investigation of the Cognitive Activity Between the Leaf Extracts of Eclipta alba and Ziziphus jujuba in Diabetic Animal Models
Ziziphus jujuba and Eclipta alba leaf extracts improve blood sugar levels and cognitive function in diabetic rats.
research What's New: Newly Approved Drugs for Children
In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.
research Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents
Pranlukast and mirabegron may work as new diabetes drugs.
research Pharma maker recalls drug over undeclared anti-hypertensive drug
A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
research A case of telogen effluvium associated with drug-induced hyperprolactinemia.
A woman's temporary hair loss was caused by high prolactin levels from her medication.
research Psychopharmacological Treatment of Trichotillomania in an Adolescent Case: Significant Improvement with Aripiprazole Augmentation
Adding aripiprazole to the treatment improved hair-pulling symptoms in a teenager.
research Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis
Certain existing drugs, like glycopyrronium and botulinum toxin type A, may help treat excessive sweating.
research Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action
Methylene blue, combined with ceramides, may reduce skin and hair side effects from GLP-1 therapy.
research An industry update: what’s new in the field of therapeutic delivery this month?
New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
research Rapid hair depigmentation in patient treated with pazopanib
Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
research 5-Alpha Reductase Inhibitors on Hypersexuality During the Manic Phase of Bipolar and Psychotic Patients; New Insight to a Well-Known Medicines
research Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium
Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
research Antipsoriatic Activity of a New Synthetic Retinoid
The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.
research Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression
Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
research Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature
Long-term use of Risperidone may be linked to a serious skin condition in bipolar patients, affecting their overall well-being.
research NEW PROPRIETARY BRANDS: Cephalexin
Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
research THU372 Finasteride Induced Hyperglycemia
Finasteride may worsen blood sugar control in diabetic patients.
research Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
research Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
GLP-1 agonists may increase the risk of hair loss.
research 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations
GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.
research RSPO1, a potent inducer of pancreatic β cell neogenesis
RSPO1 could help create new diabetes treatments by increasing pancreatic β cells.
research A smart polyhydroxyalkanoate-hyaluronic acid hybrid biphasic delivery platform for enhanced Alzheimer’s symptom management via sustained huperzine A release
The new delivery system improves Alzheimer's symptoms by releasing Huperzine A slowly and effectively.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
GLP-1RA therapy may increase the risk of hair loss.
research GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.